XML 34 R23.htm IDEA: XBRL DOCUMENT
v3.21.1

Stockholders' Equity (Tables) | 9 Months Ended
--- | ---
Sep. 30, 2020
Stockholders' Equity Note [Abstract] |
Schedule of outstanding warrants and options |
|  | Warrant Grants |  |  | Stock Option Grants |  |  | Restricted Stock Units |
|  | Number of shares subject to warrants |  |  | Weighted- average exercise price per share |  |  | Number of shares subject to options |  |  | Weighted- average exercise price per share |  |  | Number of shares subject to restricted stock units |  |  | Weighted- average exercise price per share |
Balance at December 31, 2019 |  |  | 1,311,916 |  |  | $ | 9.35 |  |  |  | 338,595 |  |  | $ | 5.26 |  |  |  | 630,303 |  |  | $ | - |
Granted |  |  | 100,000 |  |  |  | 4.75 |  |  |  | - |  |  |  | - |  |  |  | 2,222,984 |  |  |  | - |
Exercised |  |  | (681,619 | ) |  |  | 5.57 |  |  |  | (160,291 | ) |  |  | 4.78 |  |  |  | (46,931 | ) |  |  | - |
Cancelled/Forfeited |  |  | (88,027 | ) |  |  | 31.24 |  |  |  | (5,263 | ) |  |  | 24.70 |  |  |  | (475,000 | ) |  |  | - |
Balance at September 30, 2020 |  |  | 642,270 |  |  | $ | 9.71 |  |  |  | 173,041 |  |  | $ | 5.12 |  |  |  | 2,331,356 |  |  | $ | - |
Exercisable at September 30, 2020 |  |  | 642,270 |  |  | $ | 9.71 |  |  |  | 173,041 |  |  | $ | 5.12 |  |  |  | 642,311 |  |  | $ | - |
Schedule of black-scholes option-pricing model to value the warrant |
|  | Issuance dates |
Risk-free interest rate |  |  | 1.00 | %
Expected dividend yield |  |  | 0 | %
Expected volatility |  |  | 100 | %
Term |  |  | 5 years |
Fair value of common stock |  | $ | 2.37 |
Schedule of outstanding warrants and options |
Warrants Outstanding |  | Warrants Exercisable
Exercise Price Range |  | Number Outstanding |  |  | Weighted Average Remaining Contractual Life (in years) |  |  | Weighted Average Exercise Price |  |  | Number Exercisable |  | Weighted Average Exercise Price |  |  | Intrinsic Value |
$3.80 - $141.17 |  |  | 642,270 |  |  |  | 3.03 |  |  | $ | 9.71 |  |  | 642,270 |  | $ | 9.71 |  |  |  | - |
Options Outstanding |  | Options Exercisable
Exercise Price Range |  | Number Outstanding |  |  | Weighted Average Remaining Contractual Life (in years) |  |  | Weighted Average Exercise Price |  |  | Number Exercisable |  | Weighted Average Exercise Price |  |  | Intrinsic Value |
$2.64 - $28.50 |  |  | 173,041 |  |  |  | 3.61 |  |  | $ | 5.12 |  |  | 173,041 |  | $ | 5.12 |  |  |  | - |
Schedule of stock-based compensation expense categorized of equity components |
|  | For the three months ended |  |  | For the nine months ended |
|  | September 30, |  |  | September 30, |
|  | 2020 |  |  | 2019 |  |  | 2020 |  |  | 2019 |
Stock-based compensation expense |  | $ | 488,304 |  |  | $ | 433,438 |  |  | $ | 2,844,851 |  |  | $ | 6,283,811 |
Schedule of stock-based compensation expense |
|  | For the three months ended |  |  | For the nine months ended |
|  | September 30, |  |  | September 30, |
|  | 2020 |  |  | 2019 |  |  | 2020 |  |  | 2019 |
Common stock |  | $ | 488,307 |  |  | $ | 359,910 |  |  | $ | 2,844,851 |  |  | $ | 764,807 |
Stock option awards |  |  | - |  |  |  | 73,528 |  |  |  | - |  |  |  | 196,074 |
Transfer of common stock by founders to contractors |  |  | - |  |  |  | - |  |  |  | - |  |  |  | 5,322,930 |
Total |  | $ | 488,307 |  |  | $ | 433,438 |  |  | $ | 2,844,851 |  |  | $ | 6,283,811 |

X
- Definition Tabular disclosure of all significant concentrations of risk, including credit risk and market risk, arising from all financial instruments (as defined), whether from an individual counterparty or groups of counterparties. The disclosure concerning concentrations of risk may consist of the following information: (1) for concentrations of credit risk disclosure may include: (a) information about the (shared) activity, region, or economic characteristic that identifies the concentration, (b) the maximum amount of loss due to credit risk that, based on the gross fair value of the financial instrument, the entity would incur if parties to the financial instruments that make up the concentration failed completely to perform according to the terms of the contracts and the collateral or other security, if any, for the amount due proved to be of no value to the entity, (c) the policy of requiring collateral or other security to support financial instruments subject to credit risk, information about the entity's access to that collateral or other security, and the nature and a brief description of the collateral or other security supporting those financial instruments, and (d) the policy of entering into master netting arrangements to mitigate the credit risk of financial instruments, information about the arrangements for which the entity is a party, and a brief description of the terms of those arrangements, including the extent to which they would reduce the entity's maximum amount of loss due to credit risk and (2) for disclosure of quantitative information about the market risks of financial instruments that is consistent with the way the company manages or adjusts those risks, disclosure may include: (a) more details about current positions and perhaps activity during the period, (b) the hypothetical effects on comprehensive income (or net assets), or annual income, of several possible changes in market prices, (c) a gap analysis of interest rate re-pricing or maturity dates, (d) the duration of the financial instruments, (e) the entity's value at risk from derivatives and from other positions at the end of the reporting period and the average value at risk during the year, or (f) other ways of reporting quantitative information as internally developed. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 22 -URI http://asc.fasb.org/extlink&oid=121572278&loc=d3e13572-108611 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 20 -URI http://asc.fasb.org/extlink&oid=121572278&loc=d3e13531-108611 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 23 -URI http://asc.fasb.org/extlink&oid=121572278&loc=d3e13587-108611 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 21 -URI http://asc.fasb.org/extlink&oid=121572278&loc=d3e13537-108611 + Details
Name: | us-gaap_FairValueConcentrationOfRiskTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (d) -URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (e) -URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c)(1) -URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901 + Details
Name: | us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_StockholdersEquityNoteAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | worx_ScheduleOfOutstandingWarrantsAndOptions
Namespace Prefix: | worx_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Schedule of stock-based compensation expense. + References No definition available. + Details
Name: | worx_ScheduleOfStockbasedCompensationExpenseTableTextBlock
Namespace Prefix: | worx_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the components of stock-based compensation expense categorized by equity components. + References No definition available. + Details
Name: | worx_StockbasedCompensationExpenseCategorizedByEquityComponentsTableTextBlock
Namespace Prefix: | worx_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration